While there have been successes with targeted therapies in pediatric cancers, such as GD2-directed therapies in neuroblastoma31, entrectinib, larotrectinib8 and other TRK-fusion kinase inhibitors in NTRK-fusion-positive solid tumors32, BRAF, MEK, and pan-RAF inhibitors in gliomas with BRAF alterations33, a large proportion of pediatric solid tumors do not contain immediately targetable abnormalities34. This evidence concerns the gene MAP2K7 and cancer.